NovoCure Ltd Insider Trading for April 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd for April 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 216.69 | 600 | 130,016 | 555,393 | 556 K to 555.4 K (-0.11 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 214.67 | 500 | 107,333 | 555,993 | 556.5 K to 556 K (-0.09 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 213.35 | 1,500 | 320,021 | 556,493 | 558 K to 556.5 K (-0.27 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 211.28 | 600 | 126,766 | 557,993 | 558.6 K to 558 K (-0.11 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 210.18 | 521 | 109,504 | 558,593 | 559.1 K to 558.6 K (-0.09 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 209.34 | 2,200 | 460,555 | 559,114 | 561.3 K to 559.1 K (-0.39 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 207.80 | 4,500 | 935,118 | 561,314 | 565.8 K to 561.3 K (-0.80 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 206.35 | 1,284 | 264,956 | 565,814 | 567.1 K to 565.8 K (-0.23 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 205.43 | 1,600 | 328,690 | 567,098 | 568.7 K to 567.1 K (-0.28 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 204.28 | 1,972 | 402,834 | 568,698 | 570.7 K to 568.7 K (-0.35 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 203.25 | 2,555 | 519,311 | 570,670 | 573.2 K to 570.7 K (-0.45 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 202.16 | 4,388 | 887,069 | 573,225 | 577.6 K to 573.2 K (-0.76 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 201.55 | 4,125 | 831,377 | 577,613 | 581.7 K to 577.6 K (-0.71 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 199.71 | 4,338 | 866,355 | 581,738 | 586.1 K to 581.7 K (-0.74 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 198.98 | 10,563 | 2,101,794 | 586,076 | 596.6 K to 586.1 K (-1.77 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 197.83 | 13,612 | 2,692,876 | 596,639 | 610.3 K to 596.6 K (-2.23 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 197.00 | 24,338 | 4,794,659 | 610,251 | 634.6 K to 610.3 K (-3.84 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 196.07 | 8,814 | 1,728,187 | 634,589 | 643.4 K to 634.6 K (-1.37 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 194.94 | 1,600 | 311,904 | 643,403 | 645 K to 643.4 K (-0.25 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 193.57 | 2,090 | 404,563 | 645,003 | 647.1 K to 645 K (-0.32 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 192.52 | 1,900 | 365,796 | 647,093 | 649 K to 647.1 K (-0.29 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | DOYLE WILLIAM F | Executive Chairman | Sell | S | 191.26 | 1,400 | 267,768 | 648,993 | 650.4 K to 649 K (-0.22 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Danziger Asaf | Chief Executive Off ... | Sell | S | 196.34 | 97,973 | 19,236,323 | 8,184 | 106.2 K to 8.2 K (-92.29 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Option Exercise | M | 31.45 | 6,000 | 188,700 | 6,345 | |
| Apr 15 2021 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 200.00 | 2,500 | 500,000 | 72,045 | 74.5 K to 72 K (-3.35 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Sell | S | 198.01 | 3,500 | 693,035 | 74,545 | 78 K to 74.5 K (-4.48 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | Buy | M | 31.45 | 6,000 | 188,700 | 78,045 | 72 K to 78 K (+8.33 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 69.37 | 3,474 | 240,991 | 19,404 | |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 83.30 | 651 | 54,228 | 3,904 | |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 47.56 | 1,833 | 87,177 | 10,998 | |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 3,474 | 694,800 | 33,259 | 36.7 K to 33.3 K (-9.46 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 69.37 | 3,474 | 240,991 | 36,733 | 33.3 K to 36.7 K (+10.45 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 651 | 130,200 | 33,259 | 33.9 K to 33.3 K (-1.92 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 83.30 | 651 | 54,228 | 33,910 | 33.3 K to 33.9 K (+1.96 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 1,833 | 366,600 | 33,259 | 35.1 K to 33.3 K (-5.22 %) |
| Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 47.56 | 1,833 | 87,177 | 35,092 | 33.3 K to 35.1 K (+5.51 %) |
| Apr 08 2021 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 72.22 | 3,670 | 265,029 | 150,014 | 153.7 K to 150 K (-2.39 %) |